Objective: This study aimed to examine the anti-in ammatory properties of boric acid(BA) in treatingknee osteoarthritis(KOA) in rats, evaluating its biochemical and histopathological therapeutic effects.Methods: The KOA rat model was induced by injecting monosodium iodoacetate into the knee joint.Random assignment was performed for the experimental groups as follows: group-1(control), group-2(KOA control), group-3(BA:4 mg/kg,orally), group-4(BA:10 mg/kg,orally), group-5 (BA:4 mg/kg,intraarticularly), and group-6(BA:10 mg/kg,intra-articularly). The rats received 100 µL of BA intra-articularly on days 1,7,14, and 21 or 1 mL orally once a day (5 days/week) for 4 weeks. Serum levels of interleukin-1β (IL-1β), tumor necrosis factor-α(TNF-α), and matrix metalloproteinase-13(MMP-13) were measured.Histopathological and immunohistochemical analyses were performed on knee joint samples using speci c antibodies for IL-1β, TNF-α, MMP13, and nitric oxide synthase-2(NOS-2).Results. Group-2 exhibited higher serum levels of IL-1β, TNF-α, and MMP-13 than group-1(P<0.05).However, these levels were lower in all treatment groups compared to group-2, with statistically signi cant reductions observed in groups-4,5, and 6. Histopathologically, group-2 displayed joint space narrowing, cartilage degeneration, and deep ssures. Groups-5 and 6 demonstrated signi cant joint space enlargement, articular cartilage tissue regeneration, and immunostaining patterns similar to those in group-1. Immunohistochemically, group-2 showed signi cant increases in IL-1β, TNF-α, MMP-13, and NOS-2 expression. However, all treatment groups exhibited reductions in these expression levelscompared to group-2, with statistically signi cant decreases observed in groups-5 and 6(P<0.01).Conclusions. BA shows potential e cacy in reducing in ammation in experimental KOA models in rats. It may be a promising therapeutic agent for KOA, warranting further clinical studies for validation.
Key Points1. This study represents the rst evidence demonstrating the effectiveness of boric acid (BA) in alleviating symptoms of knee osteoarthritis (KOA) using an experimental rat model.2. Speci cally, BA effectively reduces the levels of in ammatory cytokines, including metalloproteinase-13 (MMP-13), tumor necrosis factor-alpha (TNF-α), and interleukin-1beta (IL-1β), both in the serum and knee joint samples of the experimental KOA rat model.3. The application of BA through intra-articular (i.a.) administration has been shown to signi cantly decrease proin ammatory cytokines, as evidenced by histopathological, immunohistochemical, and biochemical analyses, indicating its potential as an alternative treatment option for KOA.